University of Iowa Hospitals and Clinics
The purpose of this study is to learn more about the safety and effects of Kalyedco in subjects with CF who are 6 years old and older, with at least one copy of the R117H-CFTR mutation. We will also look at how Kalyedco may affect your body and how your body breaks down and eliminates ivacaftor.
Mary Teresi PharmD firstname.lastname@example.org
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.